Compare ADMA Biologics Inc (ADMA) vs AMETEK, Inc. (AME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs AMETEK, Inc. — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while AMETEK, Inc. trades at $228.58 (market cap $53.11B). The key difference: AMETEK, Inc. is far larger — about 24.9× ADMA Biologics Inc's market cap, and AMETEK, Inc. pays a 0.59% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AME | |
|---|---|---|
Market Cap | $2.13B | $53.11B |
Sector | Health | Industrials |
52-Week High | $20.38 | $241.94 |
52-Week Low | $7.60 | $176.44 |
Enterprise Value | $2.20B | $54.80B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AME trades at $231.70, down 1.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $263.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.97 exceeding expectations. Revenue grew to $7.40 billion in 2025, and net income margin improved to 20.11%. Recent acquisitions, including First Aviation Services and the Indicor Instrumentation group for $5 billion, aim to expand its aerospace and industrial technology footprint.
The outlook for AME is positive, supported by earnings momentum, strategic acquisitions, and solid profitability. Risks include integration challenges from large acquisitions and elevated valuation multiples, such as a P/E of 35.82. With no sell ratings from analysts and institutional backing, the stock presents a growth opportunity, though investors should monitor execution on acquisition synergies and macroeconomic conditions affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
